Clinical Trial: Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

U.S., Sept. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07157774) titled 'Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)' on Aug. 28.

Brief Summary: The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.

Study Start Date: Sept. 02

Study Type: INTERVENTIONAL

Condition: Elevated Lp(a) Atherosclerotic Cardiovascular Disease (ASCVD)

Intervention: DRUG: Muvalaplin

Administered orally

DRUG: Placebo

Administered orally

Recruitment Status: RECRUITING

Sponsor: Eli Lilly and Company

Publ...